
Prothena (PRTA) Stock Forecast & Price Target
Prothena (PRTA) Analyst Ratings
Bulls say
Prothena Corp PLC is advancing its clinical pipeline with promising investigational therapeutics aimed at addressing significant neurodegenerative and rare diseases, such as AQ amyloidosis, Parkinson's disease, and Alzheimer's. The company has forecasted the potential to earn up to $105 million in aggregate milestones by 2026 from collaborations with Novo Nordisk and Bristol-Myers Squibb, indicating strong potential revenue growth tied to product development advancements. Additionally, despite some safety concerns regarding elevated ARIA levels, products like PRX012 have demonstrated favorable efficacy profiles and good tolerability, supporting a positive outlook for the company’s future performance.
Bears say
Prothena Corp PLC is facing a challenging outlook due to its ongoing net losses, which are expected to persist until at least the approval and commercialization of its therapeutic products, potentially extending into the early launch phase. The company's reliance on additional capital raises poses an uncertain and dilutive impact on shareholder value, complicating its financial stability. Furthermore, regulatory risks associated with the changing stance on drug approvals for specific diseases and molecular classes may present significant obstacles to the company's success.
This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.
Prothena (PRTA) Analyst Forecast & Price Prediction
Start investing in Prothena (PRTA)
Order type
Buy in
Order amount
Est. shares
0 shares